In this critical time, the FDA Oncology Center of Excellence wants you to know that we are here for patients with cancer and their health care providers and we will do everything we can to help you through the coronavirus crisis.
Dr. Breelyn Wilky, Director of Sarcoma Translational Research at the University of Colorado Cancer Center shares about Cancer vs. Coronavirus in her latest blog post covering hospital visits, keeping appointment scans, and risk factors for GIST patients.
These are trying times for everyone. As we move into uncharted territory created by the coronavirus pandemic, it is normal for the average person to experience fearful thoughts. Add to the mix fears that are ever present for those with a cancer diagnosis and you have a formula for anxiety.
The Life Raft Group is facing the same challenges we all are in light of this health crisis. We are doing our best on a daily basis to do the right thing in all matters impacting the well-being of our patients, caregivers, staff and everyone we serve.
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Alan Henderson shares his story.
Drug repository programs have the potential to be a key component in accessing life-saving treatments. In a landscape where prices for cancer drugs are escalating, many face a challenge in obtaining life-saving treatments. There are many resources for overcoming these obstacles, but it is clearly not enough for those already struggling with the challenges of a cancer diagnosis.
Senior Scientific Director Pete Knox reports on current and emerging GIST treatments and the mutations they address. New research in GIST is happening, and there may be even more therapies around the corner.
When facing a diagnosis of cancer, self-advocacy becomes an important survival skill for patients and caregivers. These stories illustrate what an ordinary person can accomplish due to extraordinary circumstances and how they affected change for so many people with GIST.
LRG members Jennifer & Owen Moore give their perspective on participating in the Phase I BLU-285 trial at OSHU with Dr. Michael Heinrich. After three other drug treatment lines and faced with several growing tumors, the BLU-285 (avapritinib) trial was Owen’s best option.
Being diagnosed with a rare cancer like GIST can make finding resources more challenging. While this is not an exhaustive list of resources available, these organizations can provide a wealth of information and assistance.
